← Eichor
Study identifier: NCT06131840 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Condition: Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms  ·  Sponsor: Seagen, a wholly owned subsidiary of Pfizer

PhasePhase 1
Planned participants914
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Participants in this study must have cancer that has come back or did not get better with treatment. Participants must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called PF-08046050. PF-08046050 is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will test the safety of PF-08046050 in participants with solid tumors that are hard to treat or have spread throughout the body. This study has 5 different study parts. Part A and Part B of the study will find out how much PF-08046050 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046050 is safe and if it works to treat certain solid tumor cancers. Part D and E of the study, together with information from Parts A and B, will find out how much PF-08046050 should be given in combination with other anti-…

This description comes directly from the study's public registry record.

Talk to the study team

Pfizer CT.gov Call Center  ·  1-800-718-1021  ·  ClinicalTrials.gov_Inquiries@pfizer.com

Always discuss trial participation with your own doctor first.

Locations (48)

Mayo Clinic HospitalPhoenix, Arizona, United StatesRecruiting
Mayo ClinicScottsdale, Arizona, United StatesRecruiting
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)Duarte, California, United StatesRecruiting
IP Address: City of Hope Investigational Drug Services(IDS)Duarte, California, United StatesRecruiting
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)Aurora, Colorado, United StatesRecruiting
University of Colorado HospitalAurora, Colorado, United StatesRecruiting
Florida Cancer SpecialistsOrlando, Florida, United StatesRecruiting
Sarah Cannon Research Institute at Florida Cancer SpecialistsOrlando, Florida, United StatesRecruiting
Sidney Kimmel Comprehensive Cancer at Johns HopkinsBaltimore, Maryland, United StatesRecruiting
Beth Israel Deaconess Medical CenterBoston, Massachusetts, United StatesRecruiting
START MidwestGrand Rapids, Michigan, United StatesRecruiting
Mayo Clinic Cancer CenterRochester, Minnesota, United StatesRecruiting

+ 36 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06131840